Compare Moderna, Inc. (MRNA) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PAGSEG Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: Moderna, Inc. is far larger — about 26.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and PAGSEG Inc for 26 Days on average.
| MRNA | PAGS | |
|---|---|---|
Market Cap | $78.65B | $2.94B |
Volume | 37,373,437 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $225.00 | $12.00 |
52-Week Low | $22.36 | $8.44 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $74.80B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
PAGS trades at $10.68, up 1.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong fundamentals with a P/E of 7.1, net income margin of 10.45%, and a dividend yield supported by a recent $0.28 payout. Recent earnings beat expectations in Q2 2026, and cash flow from operations remains robust at $7.56 billion for 2025.
The outlook is positive given undervaluation metrics and institutional support, but risks include a projected negative net cash flow for 2026 and high RSI levels suggesting overbought conditions. Earnings growth and banking segment expansion are key catalysts, while macroeconomic pressures in Brazil present headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
